Distinct and Convergent Effects of Mutations in Human Breast Cancer

Characterization of the largest SF3B1 mutant breast cancer clinical cohort to date identifies SF3B1 driver mutations in approximately 2.5% of HR⁺ HER2^– breast cancer, with strong enrichment of K700E substitution.